Clinical trial · Observational
Role of Endocrine Disruptors in Thyroid Cancer
Cross-sectional Case-control Study on the Role of Endocrine Disruptors in Thyroid Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
the relationship between human exposure to EDCS and TC is poorly investigated and still unclear. The aim of this study is to evaluate the possible role of old and new generation endocrine disruptors in thyroid cancer. The primary aim is to evaluate the difference in the average levels of the main endocrine disruptors (PFAS, including: PFOA, PFOS, PFDA, PFUnA, PFHpS and possibly subsequently other categories, such as bisphenols, phthalates, parabens, PCBs, flame retardants) between patients with and without a diagnosis of thyroid cancer through highly sensitive, selective and precise mass spectrometry methods, such as liquid chromatography combined with tandem mass spectrometry (LC-MS / MS). The secondary aim is to evaluate the relationship between the concentrations of endocrine disruptors and some anamnestic variables studied (for example the type of diet, the use of personal care products).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endocrine Disruptor Chemicals | — | UNRESOLVED | — |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood and urine diagnostic evaluation | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Case group
- description
- Patients with thyroid cancer diagnosis within 5 years before study enrollment
- interventionNames
- Diagnostic Test: Blood and urine diagnostic evaluation
- label
- Control group
- description
- Patients without clinical diagnosis of thyroid disease
- interventionNames
- Diagnostic Test: Blood and urine diagnostic evaluation
Primary outcomes (2)
- measure
- Difference in the average levels of the main endocrine disruptors
- timeFrame
- At recruitment
- description
- The main endocrine disruptors evaluated will be PFAS, including: PFOA, PFOS, PFDA, PFUnA, PFHpS and possibly subsequently other categories, such as bisphenols, phthalates, parabens, PCBs, flame retardants
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with a diagnosis of thyroid cancer in the last 5 years (arm A) * patients without a diagnosis of thyroid cancer will match patients included in arm A Exclusion Criteria: * subjects under 18 years old * patients unable to sign the informed consent or questionnaires
References
Publications (0)
Data not yet available